Polo样激酶1在喉鳞状细胞癌中的表达及意义

发布时间：2018-07-27 20:19

【摘要】：目的： 研究Polo样激酶1 (polo-like kinase 1, PLK1)在喉鳞状细胞癌(laryngeal squamous cell carcinoma, LSCC)中的表达情况及与临床病理因素的关系,探讨PLK1在LSCC发生发展中的作用及临床意义。 方法： 收集和筛选临床资料,对符合条件的资料进行分组,分别用免疫组化和Western blot两种方法检测PLK1在LSCC和癌旁组织中的表达情况。用免疫组织化学的有70例LSCC和21例癌旁组织,用Western blot检测23对新鲜LSCC和癌旁组织。并对70例LSCC患者进行术后随访,研究PLK1的表达与LSCC的预后关系。用统计学的方法对所得数据进行统计学分析。 结果： 1.免疫组化结果显示：PLK1蛋白阳性表达具有异质性,胞浆和胞核均有表达,胞浆呈棕色,胞核呈深棕色或棕褐色,以胞浆着色为主,LSCC和癌旁组织中总的阳性表达率分别为68.6%和28.6%。前者高于后者,差异有统计学意义(P0.05)。 2. Western blot结果显示：在23对LSCC及癌旁组织新鲜标本中,有4对为LSCC和癌旁组织共同阳性表达；有12对为LSCC阳性表达,癌旁组织为阴性表达；1对为LCSS表达为阴性,而癌旁组织阳性表达；6对组织为LSCC和癌旁均无阳性表达。PLK1在LSCC阳性表达16例,阳性率69.6%；癌旁组织阳性表达5例,阳性率21.7%,前者高于后者,差异有统计学意义(P0.05)。 3. PLK1蛋白表达与LSCC临床病理特征的关系：免疫组化和western blot实验结果分析均显示,PLK1的表达与LSCC的分期和淋巴结转移及临床分期相关,T3-T4期肿瘤高于T1-T2期,临床Ⅲ-Ⅵ期的肿瘤高于临床Ⅰ-Ⅱ期,伴有淋巴结转移的肿瘤患者高于无淋巴结转移的患者,均有统计学意义(P0.05)；而PLK1的表达与患者的性别、LSCC的部位以及细胞分化程度无统计学相关(P0.05)。 4.PLK1蛋白表达与预后的关系：对70例LSCC患者在术后进行随访(截止时间为患者死亡或研究截止日期),随访时间在5年以上,其中失访4人,随访率94.3%。结果PLK1阳性患者的5年总生存率为37.8%(17/45),而阴性者为71.4%(15/21),差异有统计学意义(P0.05)。 结论： 1.PLK1在LSCC中的表达明显高于癌旁组织,表明在LSCC中存在着PLK1蛋白的过表达现象,提示PLK1是LSCC的一个肿瘤标记物； 2. PLK1的表达与肿瘤的分期、淋巴结转移正向相关,提示PLK1的表达可能与LSCC的恶性行为有关。PLK1的表达与患者的性别、LSCC的原发部位和细胞分化程度无关。 3. PLK1的表达和LSCC患者的预后相关,PLK1阳性患者的预后更差,PLK1有可能成为LSCC患者基因治疗的靶点和一个预后指标。
[Abstract]:Objective: to investigate the expression of polo-like kinase 1 (PLK1) in laryngeal squamous cell carcinoma (LSCC) and its relationship with clinicopathological factors, and to explore the role of PLK1 in the pathogenesis and development of LSCC and its clinical significance. Methods: the clinical data were collected and screened, and the eligible data were divided into groups. The expression of PLK1 in LSCC and adjacent tissues was detected by immunohistochemistry and Western blot respectively. There were 70 cases of LSCC and 21 cases of paracancerous tissues by immunohistochemistry. 23 pairs of fresh LSCC and adjacent tissues were detected by Western blot. 70 patients with LSCC were followed up after operation to study the relationship between the expression of PLK1 and the prognosis of LSCC. The data were analyzed statistically by statistical method. Results: 1. The results of immunohistochemistry showed that the positive expression of WPLK1 protein was heterogeneity, the cytoplasm and nucleus were brown, and the cytoplasm was dark brown or brown. The total positive expression rates in LSCC and adjacent tissues were 68.6% and 28.6%, respectively. The former was higher than the latter, the difference was statistically significant (P0.05). Western blot results showed that in 23 pairs of fresh LSCC and adjacent tissues, 4 pairs were co-positive for LSCC and paracancerous tissues, 12 pairs were LSCC positive, and 1 pair was negative for LCSS expression in paracancerous tissues. There were 16 cases of positive expression of LSCC in LSCC and 16 cases of positive expression of PLK1 in paracancerous tissues, and 5 cases of positive expression in paracancerous tissues with a positive rate of 21.7%, the former being higher than that of the latter, the difference being statistically significant (P0.05). The relationship between the expression of PLK1 protein and clinicopathological features of LSCC: the results of immunohistochemistry and western blot assay showed that the expression of pPLK1 was higher than that of T1-T2 in the stage of LSCC, lymph node metastasis and clinical stage. The clinical stage 鈪，

本文编号：2149026